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Abstract
Background: The purpose of this study was to identify the risk factors associated with fatal pulmonary
hemorrhage (PH) in patients with locally advanced non-small cell lung cancer (NSCLC), treated with
chemoradiotherapy.
Methods: The medical records of 583 patients with locally advanced NSCLC, who were treated with
chemoradiotherapy between July 1992 and December 2009 were reviewed. Fatal PH was defined as PH leading to
death within 24 h of its onset. Tumor cavitation size was defined by the cavitation diameter/tumor diameter ratio
and was classified as minimum (< 0.25), minor (≥ 0.25, but < 0.5), and major (≥ 0.5).
Results: Of the 583 patients, 2.1% suffered a fatal PH. The numbers of patients with minimum, minor, and major
cavitations were 13, 11, and 14, respectively. Among the 38 patients with tumor cavitation, all 3 patients who
developed fatal PH had major cavitations. On multivariate analysis, the presence of baseline major cavitation (odds
ratio, 17.878), and a squamous cell histology (odds ratio, 5.491) proved to be independent significant risk factors for
fatal PH. Interestingly, all patients with fatal PH and baseline major cavitation were found to have tumors with
squamous cell histology, and the occurrence of fatal PH in patients having both risk factors was 33.3%.
Conclusions: Patients at high risk of fatal PH could be identified using a combination of independent risk factors.
Background
Clinical trials have shown that properly chosen candi-
dates with locally advanced non-small cell lung cancer
(NSCLC) have a survival advantage when treated with
chemoradiotherapy, which is now a widely used mode
of treatment for such patients [1,2].
Massive pulmonary hemorrhage (PH) is one of the
most serious events observed in patients with lung can-
cer treated with chemotherapy and/or radiotherapy, and
is now highlighted by the introduction of bevacizumab
(Avastin; Genentech, South San Francisco, CA, USA),
which induce a high incidence of massive PH in a subset
of patients. Although several studies have evaluated risk
factors that are suggested to be associated with the
development of a massive PH in the setting of endo-
bronchial brachytherapy or bevacizumab therapy [3-7],
these reports included relatively small numbers of
patients or had results that lacked sufficient statistical
power. In addition, no previous reports have evaluated
the risk factors of massive PH in the setting of
chemoradiotherapy.
In the present report, we reviewed a large series of
consecutive patients with locally advanced NSCLC trea-
ted with chemoradiotherapy. The purpose of this study
was to identify risk factors associated with fatal PH in
these patients.
Methods
Patients
A total of 598 patients with stage II and III NSCLC,
treated with chemoradiotherapy between July 1992 and
December 2009 were identified in our departmental
database. Fifteen patients were excluded because a pre-
therapy chest computed tomography (CT) scan was not
available. The remaining 583 patients comprised the
study cohort. Fatal PH, defined as a PH leading to death
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medical records. PH events that were possibly caused by
an additional complicating factor such as disease pro-
gression were excluded.
Radiographic tumor characteristics
Chest CT scans of all patients were assessed by a physi-
cian blinded to the clinical history and patient status.
T h ep r e s e n c ea n ds i z eo ft h ec a v i t a t i o na sw e l la st h e
longest diameter of the largest tumor mass were evalu-
ated as potentially relevant baseline tumor characteristics.
Cavitation size was defined as the cavitation diameter/
tumor diameter ratio and was classified as minimum (<
0.25), minor (≥ 0.25 but < 0.5), or major (≥ 0.5).
Clinicopathological information
We reviewed the regularly updated clinical database of
each patient for the following clinicopathological infor-
mation: age (below or above 70 years), gender, Eastern
Cooperative Oncology Group performance status (0, 1,
or 2), smoking history (nonsmokers or ever-smokers),
TNM stage, tumor location (central or peripheral),
tumor laterality (right or left), baseline chest pain (pre-
sence or absence), baseline cough (presence or absence),
and baseline hemoptysis (presence or absence). We
included age in the analysis using 70 years as a cut-off
to provide the information on elderly patients, because
70 years is widely accepted as a cut-off point for defin-
ing the elderly population [8]. Disease stages was based
on the TNM classification of the International Union
Against Cancer, 6th edition [9]. We defined peripheral
tumors as those in which the center of the mass was
within the parenchyma and had no or minimal contact
with hilar structures. Other tumors were labeled central
tumors.
Pathological evaluation
We reviewed the medical records of each patient for
information on tumor pathology. Histological type was
determined according to the World Health Organization
classification [10].
Statistical analysis
For univariate analyses, variables were evaluated using
Fisher’s exact test. For multivariate analysis, logistic
regression was used to identify independent risk factors
related to the incidence of fatal PH. All p values
reported were 2-sided, and the significance level was set
at less than 0.05. Analyses were performed using the
statistical software SPSS 11.0 (Dr. SPSS II for Windows,
standard version 11.0; SPSS Inc., Chicago, IL, USA).
This study was conducted as part of a National Cancer
Center institutional review board-approved protocol.
Results
Table 1 shows the clinicopathological characteristics of
583 patients with locally advanced NSCLC. The patient
cohort consisted of 482 (82.7%) men and 101 (17.3%)
women. Their age range was 31-85 years with a median
of 65 years. The most predominant histological type was
adenocarcinoma (275; 47.2%), followed by squamous cell
carcinoma (208; 35.7%). Of the 583 patients, 12 (2.1%)
patients developed fatal PH. Centrally located tumors
were seen in 127 (21.8%) patients. Baseline tumor cavi-
tation was detected in 38 (6.5%) patients.
Table 2 shows the incidence of fatal PH and cavitation
diameter/tumor diameter ratio in 38 patients with base-
line tumor cavitation. The number of patients with
minimum, minor, and major cavitations were 14, 11,
and 13, respectively. Among the patients with cavitation,
all 3 patients with fatal PH had major cavitations.
On univariate analysis, squamous cell histology, a cen-
trally located tumor, and the presence of a major cavita-
tion proved to be significant risk factors for fatal PH
(Table 3). On multivariate analysis, squamous histology
(odds ratio [OR], 5.491; p = 0.040; 95% confidence inter-
val [CI], 1.079-27.943) and the presence of baseline
tumor cavitation (OR, 17.878; p = 0.001; 95% CI, 3.430-
93.190) were shown to be independent significant risk
factors for fatal PH (Table 4).
The association between tumor histological type and
the incidence of fatal PH among the patients with base-
line major cavitation (n = 14) is shown in Table 5.
Among the 14 patients with baseline major cavitation,
fatal PH occurred in 3, all of whom had squamous cell
carcinomas. The incidence of fatal PH in patients with
both baseline major cavitation and squamous cell histol-
ogy was 3/9 (33.3%).
Discussion
The treatment of locally advanced NSCLC remains con-
troversial [11] due to the heterogeneity of this patient
population. Surgery alone is not recommended as the
standard therapy, because the prognosis of these
patients varies according to the status of mediastinal
lymph node involvement. Additionally, primary surgery
has been shown to have poor outcomes in certain sub-
groups of patients with this disease [12]. The most com-
mon treatment approaches are concurrent
chemoradiation (CRT) [13,14], or in some cases trimod-
ality therapy, which involves CRT followed by surgical
resection [15,16]. Thoracic irradiation may cause a
bronchovascular fistula, which results either from the
rapid regression of the tumor or from necrosis of the
bronchial mucosa and the vessel wall by radiotherapy
itself with the attendant endothelial damage causing vas-
cular abnormalities. As the pathogenesis of PH involves
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Page 2 of 6Table 1 Clinicopathological characteristics of 583 patients treated with chemoradiotherapy
Characteristics No. of patients (%)
Overall number 583
Age (years) median (range) 65 (31-85)
≤ 70 449 (77.0)
> 70 134 (23.0)
Gender
Male 482 (82.7)
Female 101 (17.3)
ECOG PS
0 171 (29.3)
1 408 (70.0)
2 4 (0.7)
Smoking history
Nonsmoker 51 (8.7)
Ever-smoker 532 (91.3)
Stage
IIA 6 (1.0)
IIB 24 (4.1)
IIIA 209 (35.8)
IIIB 344 (59.0)
Histology
Adenocarcinoma 275 (47.2)
Squamous cell carcinoma 208 (35.7)
NSCLC 98 (16.8)
Fatal pulmonary hemorrhage
Absent 571 (97.9)
Present 12 (2.1)
Tumor loction
Central 127 (21.8)
Peripheral 456 (78.2)
Tumor laterality
Right 346 (59.3)
Left 236 (40.5)
Baseline tumor cavitation
Absent 545 (93.5)
Present 38 (6.5)
Baseline cough
Absent 317 (54.4)
Present 266 (45.6)
Baseline chest pain
Absent 484 (83.0)
Present 99 (17.0)
Baseline sputum
Absent 454 (77.9)
Present 129 (22.1)
Baseline hoarseness
Absent 536 (91.9)
Present 47 (8.1)
Baseline hemoptysis
Absent 468 (80.3)
Present 115 (19.7)
ECOG PS: Eastern Cooperative Oncology Group Performance Status, NSCLC: non-small cell lung cancer
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[5,17], thoracic irradiation is a potential cause of PH,
and its toxicity may be enhanced when combined with
chemotherapy [18].
This study was conducted to identify the risk factors
for fatal PH in patients with locally advanced NSCLC
treated with chemoradiotherapy. Risk factors for fatal
PH in this set of patients have not yet been established.
In the current study, risk factors were determined by
multiple logistic regression of variables that included
patient demographics, baseline hemoptysis, tumor loca-
tion, histological type, and baseline tumor cavitation, all
of which could influence the occurrence of PH. We
identified 2 independent significant risk factors for fatal
PH: the presence of baseline major cavitation and squa-
mous cell histology. The presence of baseline major
cavitation proved to be a powerful risk factor (OR,
17.878) for fatal PH. Chaudhuri et al. examined cavitat-
ing lung cancer and reported that vascular invasion by
tumor cells causes intratumoral ischemia [19], which
induces hypoxia-inducible transcription factors and sev-
eral angiogenic factors such as vascular endothelial
growth factors [20]. The mechanism of PH in tumors
with cavitation remains unclear, but disruption of the
abnormal intratumoral vasculature by these transcrip-
tion factors or cytokines may be one of the causes of
PH in case of tumors with cavitation.
W h i l et h ei n c i d e n c eo fP Ha p p e a r e dt ob eh i g hi n
patients with squamous cell carcinoma, it remains
unclear whether squamous cell carcinoma contributed
directly to the hemorrhage. For example, the risk of PH
observed in the first phase I clinical trial of bevacizumab
rendered antiangiogenic therapies inaccessible to patients
with squamous cell carcinoma; [21] nevertheless, bevaci-
zumab was added to standard frontline chemotherapy for
NSCLC and has shown a survival benefit in these patients
compared to chemotherapy alone [22,23]. However, it
was not clear whether histology alone was the central
risk factor for PH since squamous cell tumors differed
from adenocarcinomas in that they were more frequently
centrally located and had a greater tendency to cavitate.
In the current study, we showed that squamous cell his-
tology was associated with PH, independent of tumor
location or the presence of cavitation.
Interestingly, the tumors of all patients with fatal PH
who had major tumor cavitation before treatment had
squamous cell histology. The incidence of fatal PH in
patients having both risk factors, baseline major cavita-
tion and squamous cell histology, was 33.3%; in contrast,
the overall incidence in the study cohort was 2.1%. This
Table 2 Incidence of fatal PH by baseline tumor
cavitation diameter/tumor diameter ratio
No. of patients (n = 38)
Cavitation diameter/tumor diameter Non-fatal PH Fatal PH
≥ 0.5 11 3
≥ 0.25, but < 0.5 11 0
< 0.25 13 0
PH: pulmonary hemorrhage
Table 3 Correlation between fatal PH and pathological
characteristics
No. of patients (%) P
value†
Characteristics Non-fatal
PH
Fatal
PH
Overall number 571 12 (2.1)
Age (y) median (range) 65 (31-85)
≤ 70 437 (76.5) 12 (100) 0.078
> 70 134 (23.5) 0 (0)
Gender
Male 472 (82.7) 10 (83.3) 1.000
Female 99 (17.3) 2 (16.7)
ECOG PS
0 170 (29.8) 1 (8.3) 0.196
1, 2 401 (70.2) 11 (91.7)
Smoking history
Non smoker 51 (8.9) 0 (0) 0.613
Ever-smoker 520 (91.1) 12 (100)
Histology
Squamous cell
carcinoma
198 (34.7) 10 (83.3) < 0.001*
Nonsquamous NSCLC 373 (65.3) 2 (16.7)
TNM stage
II 30 (5.3) 0 (0) 1.000
III 541 (94.7) 12 (100)
Tumor laterality
Right 341 (59.7) 5 (41.7) 0.242
Left 230 (40.3) 7 (58.3)
Tumor location
Central 121 (21.2) 6 (50.0) 0.028*
Peripheral 450 (78.8) 6 (50.0)
Major cavitation
Absent 560 (98.1) 9 (75.0) < 0.001*
Present 11 (1.9) 3 (25.0)
Baseline cough
Absent 313 (54.8) 4 (33.3) 0.155
Present 258 (45.2) 8 (66.7)
Baseline chest pain
Absent 475 (83.2) 9 (75.0) 0.438
Present 96 (16.8) 3 (25.0)
Baseline hemoptysis
Absent 458 (80.2) 10 (83.3) 1.000
Present 113 (19.8) 2 (16.7)
* indicates significance, †Fisher’s exact test, PH: pulmonary hemorrhage, ECOG
PS: Eastern Cooperative Oncology Group Performance Status, NSCLC: non-
small cell lung cancer, Major cavitation is defined as its cavitation/tumor
diameter ratio ≥ 0.5
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significant risk factors may enable the identification of
patients at high risk of fatal PH.
Considering the risk factors for fatal PH identified
here, primary surgery may be one of the treatment
options for patients with operable locally advanced
NSCLC, with baseline major cavitation and squamous
cell histology. For the management of massive and
recurrent hemoptysis, bronchial artery embolization
(BAE) is also a demonstrated treatment option [24-31];
however, the bleeding recurrence rate among patients
with BAE-treated lung cancer can reach 50% [32]. Surgi-
cal intervention, in contrast, is curative [33] and an
established treatment for PH. A surgical approach may
be beneficial for these patients at high risk of fatal PH
with regard to local control of the potential source of
the hemorrhage. In addition, although it remains unclear
whether chemoradiation contributes directly to the
occurrence of fatal PH in this study, primary surgical
resection may help avoid potentially unfavorable primary
chemoradiation.
T h ep r e s e n ts t u d yw a sr e t r o s p e c t i v ea n dh a dl i m i t a -
tions. It was not designed to evaluate the association
between therapeutic modality and fatal PH risk. To our
knowledge, no definitive information evaluates the direct
association between therapeutic modality and fatal PH
risk. Accordingly, it remains unclear which therapeutic
modality among surgery, chemotherapy, and
radiotherapy should be selected for patients identified as
being at high risk of fatal PH in our study. We consider
primary surgery to be a potential treatment option for
patients with operable locally advanced NSCLC, who
have both baseline major cavitation and squamous cell
histology. However, further studies are required to com-
pare the risk of surgery and the risk of fatal PH that
accompanies chemotherapy or radiotherapy. Addition-
ally, a considerable number of patients with locally
advanced NSCLC are inoperable. For these patients,
further studies are required in order to compare the dif-
ferences between therapeutic modalities with regard to
treatment benefit and the risk of fatal PH accompanying
each therapy. Furthermore, since patients with fatal PH
were all ≤ 70 years of age or had stage III tumors, we
could not evaluate the correlation between age or stage
and risk of fatal PH in this study. Despite these limita-
tions, this is the first study to identify the statistically
significant independent risk factors for fatal PH in
patients with locally advanced NSCLC treated with che-
moradiotherapy. We believe that our data will be helpful
for future trials and for clinicians when determining
therapeutic strategies for patients with locally advanced
NSCLC.
Conclusions
PH is a rare but life-threatening event that occurs in
NSCLC. Patients at high risk of fatal PH may be identi-
fied by a combination of the independent risk factors–
major baseline cavitation and squamous cell histology.
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